TRZ-4(MMAF+DXd)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameTRZ-4(MMAF+DXd)
Drug Alias NameTrastuzumab monomethyl auristatin F-exatecan derivative conjugate therapeutic (CHO Pharma/TE-Meds)1TRZ is conjugated to 4 molecules each of MMAF and DXd (CHO Pharma/TE-Meds)TRZ4/MMAF/DXdTRZ4 MMAF+DXdTRZ+4MMAF+4DXd
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin polymerisation inhibitorsDNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2TubulinDNA topoisomerase I
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCho Pharma IncT-E Meds Inc
China Registration ClassN/A

Develop Information

Active CompaniesT-E Meds Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A